Host |
Rabbit |
Klon |
ZR275 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
Lokalisation |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
7 ml |
Ready-to-use |
CE/IVD |
Z2591RP |
-
|
Host |
Rabbit |
Klon |
ZR275 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
Lokalisation |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
0.5 ml |
Concentrate |
CE/IVD |
Z2591RS |
-
|
Host |
Rabbit |
Klon |
ZR275 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
Lokalisation |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
0.1 ml |
Concentrate |
CE/IVD |
Z2591RT |
-
|
Host |
Rabbit |
Klon |
BC36 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1/Kappa |
Lokalisation |
Nucleus |
SOX2
|
Biocare Medical |
BC36 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3109A |
-
|
Host |
Rabbit |
Klon |
BC36 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1/Kappa |
Lokalisation |
Nucleus |
SOX2
|
Biocare Medical |
BC36 |
1 ml |
Concentrate |
CE/IVD |
ACI3109C |
-
|
Host |
Rabbit |
Klon |
BC36 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
- |
Isotyp |
IgG1/Kappa |
Lokalisation |
Nucleus |
SOX2
|
Biocare Medical |
BC36 |
6 ml |
Ready-to-use |
CE/IVD |
API3109AA |
-
|
Host |
Monospecific Mouse |
Klon |
ZM57 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal brain tissue and astrocytoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX2 protein fragment (around aa176-305) |
Lokalisation |
Nucleus |
SOX2
|
Zeta Corporation |
ZM57 |
1 ml |
Concentrate |
CE/IVD |
Z2367ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM57 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal brain tissue and astrocytoma. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX2 protein fragment (around aa176-305) |
Lokalisation |
Nucleus |
SOX2
|
Zeta Corporation |
ZM57 |
7 ml |
Ready-to-use |
CE/IVD |
Z2367MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM57 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal brain tissue and astrocytoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX2 protein fragment (around aa176-305) |
Lokalisation |
Nucleus |
SOX2
|
Zeta Corporation |
ZM57 |
0.5 ml |
Concentrate |
CE/IVD |
Z2367MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM57 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal brain tissue and astrocytoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX2 protein fragment (around aa176-305) |
Lokalisation |
Nucleus |
SOX2
|
Zeta Corporation |
ZM57 |
0.1 ml |
Concentrate |
CE/IVD |
Z2367MT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM171 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human pancreas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human SOX9 protein fragment (around aa393-508) |
Lokalisation |
Nucleus |
SOX9
|
Zeta Corporation |
ZM171 |
1 ml |
Concentrate |
CE/IVD |
Z2483ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM171 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human pancreas. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human SOX9 protein fragment (around aa393-508) |
Lokalisation |
Nucleus |
SOX9
|
Zeta Corporation |
ZM171 |
7 ml |
Ready-to-use |
CE/IVD |
Z2483MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM171 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human pancreas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human SOX9 protein fragment (around aa393-508) |
Lokalisation |
Nucleus |
SOX9
|
Zeta Corporation |
ZM171 |
0.5 ml |
Concentrate |
CE/IVD |
Z2483MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM171 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human pancreas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human SOX9 protein fragment (around aa393-508) |
Lokalisation |
Nucleus |
SOX9
|
Zeta Corporation |
ZM171 |
0.1 ml |
Concentrate |
CE/IVD |
Z2483MT |
-
|
Host |
Mouse |
Klon |
BC34 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
SOX10
|
Biocare Medical |
BC34 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3099A |
-
|
Host |
Mouse |
Klon |
BC34 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
SOX10
|
Biocare Medical |
BC34 |
1 ml |
Concentrate |
CE/IVD |
ACI3099C |
-
|
Host |
Mouse |
Klon |
BC34 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
SOX10
|
Biocare Medical |
BC34 |
6 ml |
Ready-to-use |
CE/IVD |
API3099AA |
-
|
Host |
Mouse |
Klon |
BC34 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
SOX10
|
Biocare Medical |
BC34 |
25 ml |
Ready-to-use |
CE/IVD |
API3099H |
-
|
Host |
Mouse |
Klon |
BC34 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nuclear |
SOX10
|
Biocare Medical |
BC34 |
25 ml |
Ready-to-use |
CE/IVD |
AVI3099H |
-
|
Host |
Monospecific Mouse |
Klon |
ZM10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX10 protein fragment (around aa115-269) |
Lokalisation |
Nucleus |
SOX10
|
Zeta Corporation |
ZM10 |
1 ml |
Concentrate |
CE/IVD |
Z2293ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM10 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Melanoma. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX10 protein fragment (around aa115-269) |
Lokalisation |
Nucleus |
SOX10
|
Zeta Corporation |
ZM10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2293MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX10 protein fragment (around aa115-269) |
Lokalisation |
Nucleus |
SOX10
|
Zeta Corporation |
ZM10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2293MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX10 protein fragment (around aa115-269) |
Lokalisation |
Nucleus |
SOX10
|
Zeta Corporation |
ZM10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2293MT |
-
|
Host |
Mouse |
Klon |
SOX11-C1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 or Diva modified Citrate pH 6.2 |
Positivkontrolle |
Mantle Cell Lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1/κ |
Lokalisation |
Nuclear |
SOX11
|
Biocare Medical |
SOX11-C1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3120A |
-
|
Host |
Mouse |
Klon |
SOX11-C1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 or Diva modified Citrate pH 6.2 |
Positivkontrolle |
Mantle Cell Lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1/κ |
Lokalisation |
Nuclear |
SOX11
|
Biocare Medical |
SOX11-C1 |
1 ml |
Concentrate |
CE/IVD |
ACI3120C |
-
|
Host |
Mouse |
Klon |
SOX11-C1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 or Diva modified Citrate pH 6.2 |
Positivkontrolle |
Mantle Cell Lymphoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1/κ |
Lokalisation |
Nuclear |
SOX11
|
Biocare Medical |
SOX11-C1 |
6 ml |
Ready-to-use |
CE/IVD |
API3120AA |
-
|
Host |
Mouse |
Klon |
SOX11-C1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Mantle Cell Lymphoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1/κ |
Lokalisation |
Nuclear |
SOX11
|
Biocare Medical |
SOX11-C1 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3120G |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
ACI135A |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
ACI135B |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
ACI135C |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
- |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
RUO |
ALR135G7 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
- |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API135AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
- |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
RUO |
AVR135G |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
IF |
Isotyp |
Rabbit IgG |
Verdünnung |
Staphylococcus aureus ATCC27660 |
Staphylococcus aureus
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
619-0198 |
-
|
Host |
Rabbit |
Klon |
ZR289 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Solitary fibrous tumor. |
Verdünnung |
1:100-200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human STAT6 protein |
Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
1.0 ml |
Concentrate |
CE/IVD |
Z2727RL |
-
|
Host |
Rabbit |
Klon |
ZR289 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Solitary fibrous tumor. |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human STAT6 protein |
Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
7ml |
ready-to-use |
CE/IVD |
Z2727RP |
-
|
Host |
Rabbit |
Klon |
ZR289 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Solitary fibrous tumor. |
Verdünnung |
1:100-200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human STAT6 protein |
Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
0.5 ml |
Concentrate |
CE/IVD |
Z2727RS |
-
|
Host |
Rabbit |
Klon |
ZR289 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Solitary fibrous tumor. |
Verdünnung |
1:100-200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human STAT6 protein |
Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
0.1 ml |
Concentrate |
CE/IVD |
Z2727RT |
-
|
Host |
Mouse |
Klon |
N1665 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortical carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
1.0 ml |
Concentrate |
CE/IVD |
Z2223ML |
-
|
Host |
Mouse |
Klon |
N1665 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortical carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
7 ml |
Ready-to-use |
CE/IVD |
Z2223MP |
-
|
Host |
Mouse |
Klon |
N1665 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortical carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
0.5 ml |
Concentrate |
CE/IVD |
Z2223MS |
-
|
Host |
Mouse |
Klon |
N1665 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortical carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
0.1 ml |
Concentrate |
CE/IVD |
Z2223MT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM124 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
1 ml |
Concentrate |
CE/IVD |
Z2428ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM124 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
7 ml |
Ready-to-use |
CE/IVD |
Z2428MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM124 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
0.5 ml |
Concentrate |
CE/IVD |
Z2428MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM124 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
0.1 ml |
Concentrate |
CE/IVD |
Z2428MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
MS, RT, BV, PG |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas, Pheochromocytoma |
Verdünnung |
1:300 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide of human synaptophysin. |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
519-2172 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
MS, RT, BV, PG |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas, Pheochromocytoma |
Verdünnung |
1:300 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide of human synaptophysin. |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
519-2174 |
-
|
Host |
Rabbit |
Klon |
SP11 |
Format |
Concentrate |
Reaktivität |
MS, RT, BV |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas or Pheochromocytoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to human Synaptophysin |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
SP11 |
0.5 ml |
Concentrate |
RUO |
519-3112 |
-
|
Host |
Rabbit |
Klon |
SP11 |
Format |
Concentrate |
Reaktivität |
MS, RT, BV |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas or Pheochromocytoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to human Synaptophysin |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
SP11 |
1 ml |
Concentrate |
RUO |
519-3114 |
-
|